Phibro Animal Health (NASDAQ:PAHC) Stock Rating Lowered by StockNews.com

Phibro Animal Health (NASDAQ:PAHCGet Free Report) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Friday.

Other equities research analysts have also recently issued reports about the stock. Bank of America lifted their price target on shares of Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a research report on Friday, August 30th. Barclays increased their target price on Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a research note on Tuesday, November 12th. JPMorgan Chase & Co. initiated coverage on shares of Phibro Animal Health in a research note on Tuesday, September 10th. They set a “neutral” rating and a $22.00 price target on the stock. Finally, Morgan Stanley raised their price objective on shares of Phibro Animal Health from $20.00 to $25.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 17th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $20.50.

Get Our Latest Report on Phibro Animal Health

Phibro Animal Health Trading Down 2.9 %

NASDAQ:PAHC traded down $0.63 on Friday, reaching $21.05. The company’s stock had a trading volume of 188,651 shares, compared to its average volume of 160,571. Phibro Animal Health has a 12-month low of $10.03 and a 12-month high of $25.98. The stock has a 50 day moving average price of $23.35 and a 200 day moving average price of $20.81. The firm has a market cap of $852.59 million, a price-to-earnings ratio of 48.95, a price-to-earnings-growth ratio of 0.58 and a beta of 0.51. The company has a quick ratio of 1.69, a current ratio of 3.23 and a debt-to-equity ratio of 1.81.

Institutional Trading of Phibro Animal Health

Hedge funds have recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new stake in Phibro Animal Health in the third quarter valued at $70,000. nVerses Capital LLC acquired a new stake in shares of Phibro Animal Health during the 3rd quarter worth about $70,000. China Universal Asset Management Co. Ltd. lifted its stake in Phibro Animal Health by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company’s stock worth $88,000 after purchasing an additional 1,522 shares during the last quarter. CWM LLC boosted its holdings in Phibro Animal Health by 190.8% in the third quarter. CWM LLC now owns 6,363 shares of the company’s stock valued at $143,000 after purchasing an additional 4,175 shares in the last quarter. Finally, Algert Global LLC purchased a new position in Phibro Animal Health in the second quarter valued at approximately $193,000. Institutional investors and hedge funds own 99.34% of the company’s stock.

About Phibro Animal Health

(Get Free Report)

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

Featured Articles

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.